Education
About Us
Working with TipRanks
Follow Us
Celadon Pharmaceuticals PLC (GB:CEL)
LSE:CEL
Total Valuation
Celadon Pharmaceuticals PLC has a market cap or net worth of £9.23M. The enterprise value is 28.51M.
Market Cap£9.23M
Enterprise Value28.51M
Share Statistics
Celadon Pharmaceuticals PLC has 68,845,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding68,845,810
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Celadon Pharmaceuticals PLC’s return on equity (ROE) is -2.26 and return on invested capital (ROIC) is -68.65%.
Return on Equity (ROE)-2.26
Return on Assets (ROA)-0.77
Return on Invested Capital (ROIC)-68.65%
Return on Capital Employed (ROCE)-0.72
Revenue Per Employee2.78K
Profits Per Employee-264.44K
Employee Count27
Asset Turnover<0.01
Inventory Turnover0.74
Valuation Ratios
The current PE Ratio of Celadon Pharmaceuticals PLC is -9.97. Celadon Pharmaceuticals PLC’s PEG ratio is 0.03.
PE Ratio-9.97
PS Ratio0.00
PB Ratio3.77
Price to Fair Value22.54
Price to FCF-3.53
Price to Operating Cash Flow-4.74
PEG Ratio0.03
Income Statement
In the last 12 months, Celadon Pharmaceuticals PLC had revenue of 75.00K and earned -7.14M in profits. Earnings per share was -0.12.
Revenue75.00K
Gross Profit1.00K
Operating Income-5.93M
Pretax Income-7.52M
Net Income-7.14M
EBITDA-6.39M
Earnings Per Share (EPS)-0.12
Cash Flow
In the last 12 months, operating cash flow was -5.55M and capital expenditures -192.00K, giving a free cash flow of -5.74M billion.
Operating Cash Flow-5.55M
Free Cash Flow-5.74M
Free Cash Flow per Share-0.08
Dividends & Yields
Celadon Pharmaceuticals PLC pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change-79.70%
50-Day Moving Average9.17
200-Day Moving Average16.35
Relative Strength Index (RSI)64.22
Average Volume (3m)94.10K
Important Dates
Celadon Pharmaceuticals PLC upcoming earnings date is Sep 25, 2025, Before Open (Not Confirmed).
Last Earnings DateApr 25, 2025
Next Earnings DateSep 25, 2025
Ex-Dividend Date―
Financial Position
Celadon Pharmaceuticals PLC as a current ratio of 2.62, with Debt / Equity ratio of 60.35%
Current Ratio2.62
Quick Ratio2.51
Debt to Market Cap<0.01
Net Debt to EBITDA-0.54
Interest Coverage Ratio-9.92
Taxes
In the past 12 months, Celadon Pharmaceuticals PLC has paid -261.00K in taxes.
Income Tax-261.00K
Effective Tax Rate0.03
Enterprise Valuation
Celadon Pharmaceuticals PLC EV to EBITDA ratio is -11.68, with an EV/FCF ratio of -11.82.
EV to Sales995.15
EV to EBITDA-11.68
EV to Free Cash Flow-11.82
EV to Operating Cash Flow-12.50
Balance Sheet
Celadon Pharmaceuticals PLC has £16.00K in cash and marketable securities with £4.78M in debt, giving a net cash position of £4.76M billion.
Cash & Marketable Securities£16.00K
Total Debt£4.78M
Net Cash£4.76M
Net Cash Per Share£0.07
Tangible Book Value Per Share£0.05
Margins
Gross margin is -275.00%, with operating margin of -7908.00%, and net profit margin of -9520.00%.
Gross Margin-275.00%
Operating Margin-7908.00%
Pretax Margin-10030.67%
Net Profit Margin-9520.00%
EBITDA Margin-8521.33%
EBIT Margin-9233.33%
Analyst Forecast
The average price target for Celadon Pharmaceuticals PLC is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―